The Technical Analyst
Keros Therapeutics Inc [KROS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Keros Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.57% $58.01
America/New_York / 16 apr 2024 @ 09:56
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 087.35 mill |
| EPS: | -5.20 |
| P/E: | -11.16 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 35.98 mill |
| Avg Daily Volume: | 0.378 mill |
| RATING 2024-04-15 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -11.16 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.90x |
| Company: PE -11.16 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$10.75 (-81.46%) $-47.26 |
| Date: 2024-04-16 |
| Expected Trading Range (DAY) |
|---|
|
$ 54.64 - 61.38 ( +/- 5.81%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-23 | Seehra Jasbir | Buy | 125 000 | Employee Stock Option (right to buy) |
| 2024-02-13 | Seehra Jasbir | Buy | 125 000 | Employee Stock Option (right to buy) |
| 2024-02-13 | Regnante Keith | Buy | 40 000 | Employee Stock Option (right to buy) |
| 2024-02-13 | Rovaldi Christopher | Buy | 150 000 | Employee Stock Option (right to buy) |
| 2024-02-13 | Cooper Simon Peter | Buy | 40 000 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 67.32 |
| Last 96 transactions |
| Buy: 1 546 013 | Sell: 365 314 |
Forecast:
11:35 - $57.43
Live Trading Signals (every 1 min)
Forecast
1: 10:05 - $57.93
Forecast 2: 10:55 - $57.56
Forecast 3: 11:35 - $57.43
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $58.01 (0.57% ) |
| Volume | 0.0070 mill |
| Avg. Vol. | 0.378 mill |
| % of Avg. Vol | 1.841 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KROS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $51.27 | N/A | Active |
|---|
KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-03-05 08:00:00 - Press Release
Keros Therapeutics To Present At Leerink Partners 2024 Global Biopharma Conference
Lexington, mass., march 05, 2024 (globe newswire) -- keros therapeutics, inc. (“keros”) (nasdaq: kros), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“tgf-ss”) family of proteins, today announced that keros' president and chief executive officer jasbir s. seehra, ph.d., will participate in a fireside chat presentation at the leerink partners 2024 global biopharma conference on tuesday, march 12, 2024 at 3:00 p.m. eastern time.
2024-02-28 16:01:00 - Press Release
Keros Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2023 Financial Results
Lexington, mass., feb. 28, 2024 (globe newswire) -- keros therapeutics, inc. (“keros” or the “company”) (nasdaq: kros), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“tgf-ss”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended december 31, 2023.
2024-01-29 08:00:00 - Press Release
Keros Therapeutics To Present At Pulmonary Vascular Research Institute 2024 Annual Congress
Lexington, mass., jan. 29, 2024 (globe newswire) -- keros therapeutics, inc. (“keros” or “we”) (nasdaq: kros), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“tgf-ss”) family of proteins, today announced that three abstracts will be presented from the ker-012 program at the pulmonary vascular research institute (“pvri”) 2024 annual congress, to be held from january 31 through february 3, 2024.
2024-01-09 08:00:00 - Press Release
Keros Therapeutics Announces Closing Of Upsized Public Offering Of Common Stock
Lexington, mass., jan. 09, 2024 (globe newswire) -- keros therapeutics, inc. (“keros” or “we”) (nasdaq: kros), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“tgf-ss”) family of proteins, today announced the closing of the previously announced underwritten public offering of 4,025,000 shares of common stock on january 8, 2024, at a public offering price of $40.00 per share, inclusive of the underwriters' exercise in full of their option to purchase up to an additional 525,000 shares of common stock at the public offering price (the “option”)...
2024-01-03 21:29:00 - Press Release
Keros Therapeutics Announces Pricing Of Upsized Public Offering Of Common Stock
Lexington, mass., jan. 03, 2024 (globe newswire) -- keros therapeutics, inc. (“keros” or “we”) (nasdaq: kros), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“tgf-ss”) family of proteins, today announced the pricing of an underwritten public offering of 3,500,000 shares of common stock, at a public offering price of $40.00 per share. the gross proceeds to keros from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $140.0 million. all of the common stock is being offered by keros...
Latest News
2024-02-28 09:51:11 - Zacks Investment Research
Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable
Keros Therapeutics, Inc. (KROS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
2024-02-21 10:56:11 - Zacks Investment Research
Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?
The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 35.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-02-12 09:51:12 - Zacks Investment Research
Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why
Keros Therapeutics, Inc. (KROS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
2024-01-31 10:56:08 - Zacks Investment Research
Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know
The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 45.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-01-29 08:00:00 - GlobeNewsWire
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that three abstracts will be presented from the KER-012 program at the Pulmonary Vascular Research Institute (“PVRI”) 2024 Annual Congress, to be held from January 31 through February 3, 2024.
2024-01-24 09:50:28 - Zacks Investment Research
Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why
Keros Therapeutics, Inc. (KROS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
2024-01-23 10:56:14 - Zacks Investment Research
Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Keros Therapeutics, Inc. (KROS) is looking like an interesting pick, as it just reached a key level of support. KROS's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
2023-11-07 08:00:00 - GlobeNewsWire
Keros Therapeutics to Present at Upcoming Healthcare Conferences
LEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:
2023-07-27 16:01:00 - GlobeNewsWire
Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
LEXINGTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors.
2023-07-24 08:00:00 - GlobeNewsWire
Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that Keros will host a conference call and webcast to provide an overview of TROPOS, its global Phase 2 clinical trial to evaluate KER-012 in combination with background therapy in patients with pulmonary arterial hypertension (“PAH”), on August 8, 2023 at 8:00 a.m. Eastern time.